# Charles River Laboratories International Inc. (CRL) fundamentals

Data as of 2026-09-08. NYSE, United States. Sector: Healthcare / Biotechnology. Price $288.50, market value $13.9 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Charles River Laboratories International Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 3.5×**. Each dollar of revenue is priced at 3.5×.
- **Price / book: 4.8×**. The shares trade at 4.8× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 35.3×**. Enterprise value is 35.3× operating earnings before depreciation, the multiple that ignores how the company is financed; above 20× is demanding.
- **Free-cash-flow yield: 2.7%** (5-yr avg 3.8%). Free cash flow equals 2.7% of the market value, below its five-year average of 3.8%, so the shares are pricier on cash than usual.

## Profitability
- **Operating margin: 2.3%**. 2.3% of revenue is left after running the business, which leaves little cushion in a downturn.
- **Net margin: -3.6%**. The company reported a net loss over the last twelve months.
- **Return on equity: -4.6%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: 2.4%**. Return on all capital, debt included, is 2.4%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -3.3%**. Each dollar of assets produces -3.3% of profit.

## Growth
- **Revenue growth (1 yr): -0.9%** (3-yr 0.3%/yr, 5-yr 6.5%/yr). Revenue fell 0.9% over the last year, against 6.5% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): -1555.0%**. Earnings per share fell 1555.0%, slower than revenue, so margins compressed.
- **Free-cash-flow growth (3 yr): 20.7%/yr**. Free cash flow has compounded at 20.7% a year over three years.

## Financial health
- **Debt to equity: 0.00**. Debt is 0.00 times equity: a conservative balance sheet.
- **Net debt / EBITDA: net cash**. Charles River Laboratories International Inc. holds more cash than debt.
- **Altman Z-score: 3.32**. A Z-score of 3.32 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Charles River Laboratories International Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (14 analysts). 14 analysts cover Charles River Laboratories International Inc.; the consensus is buy, with an average price target of $281.00 (-3% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 77.7%** (YTD 44.6%, 3-mo 59.1%). The shares are up 77.7% over twelve months including dividends.
- **From 52-week high: -4.9%** (100.0% above the low). Trading within 5% of its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 60**. An RSI of 60 is neutral.
- **Beta (1 yr): 1.22** (volatility 46%). Beta of 1.22 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=CRL · Page: https://foliofundamentals.com/stocks/crl

Not investment advice.